EUVIMEDEUVIMED entdecken
Crossref

Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®

Roberta Noseda iD, Francesca Bedussi iD, Alice Panchaud iD, Alessandro Ceschi iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Roberta Noseda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, PCSK9 Inhibitors, Pharmacovigilance. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Safety data on the use of monoclonal antibodies inhibiting proprotein convertase subtilisin/kexin type 9 in pregnancy are scarce. This study queried VigiBase®, the World Health Organization global pharmacovigilance database, to search for signals of disproportionate reporting for pregnancy outcomes with alirocumab and evolocumab. As of November 22, 2023, there were 45 safety reports of exposure to evolocumab ( N = 31) and alirocumab ( N = 14) in pregnancy. Most of them originated from Europe ( N = 25, 55.6%) and were more frequently reported by healthcare professionals ( N = 35, 77.8%). Median patient age was 37 years (25th–75th percentiles; 32–41 years). Drug exposure occurred during pregnancy in 36 (80.0%) safety reports, via paternal exposure during pregnancy in four (8.9%), during lactation in three (6.7%), and in two safety reports the time of drug exposure remained unknown. Twenty safety reports (57.8%) merely reported drug exposure, while 19 (42.2%) also reported pregnancy outcomes, however, without specific maternal toxicities or patterns of birth defects. Spontaneous abortion was reported in eight safety reports without representing a signal of disproportionate reporting compared with either the full database (reporting odds ratio, ROR, 0.06 95% confidence interval, CI 0.03–0.12) or statins (ROR 0.16, 95% CI 0.08–0.32). In conclusion, this study showed that, currently, there are no signals of increased reporting of spontaneous abortion with alirocumab and evolocumab compared with the full database and statins in VigiBase®. Notwithstanding, lack of disproportionality is not synonymous with safety and, as disproportionality analyses depend on the number of safety reports that progressively accumulate in VigiBase®, they should be repeated at regular intervals to confirm the results of the present study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedPCSK9 InhibitorsPharmacovigilanceHumansPregnancyFemaleAdultAdverse Drug Reaction Reporting SystemsDatabases, FactualPregnancy OutcomeAntibodies, MonoclonalPregnancy ComplicationsAnticholesteremic AgentsProprotein Convertase 9

Substanzen

Antibodies, Monoclonal, HumanizedevolocumabPCSK9 InhibitorsalirocumabPCSK9 protein, humanAntibodies, MonoclonalAnticholesteremic AgentsProprotein Convertase 9

Autor:innen und Institutionen

  • Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
  • Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
  • Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.
  • Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
  • Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland.

ORCID-Profile: Roberta Noseda, Francesca Bedussi, Alice Panchaud, Alessandro Ceschi

Zitieren

APA

Noseda, R., Bedussi, F., Panchaud, A., & Ceschi, A. (2024). Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3269

Vancouver

Noseda R, Bedussi F, Panchaud A, Ceschi A. Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3269

BibTeX
@article{Noseda2024,
  author = {Noseda, Roberta and Bedussi, Francesca and Panchaud, Alice and Ceschi, Alessandro},
  title = {Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3269}
}
Kostenlos starten →